Overview

* LifeVantage ( LFVN ) fiscal Q1 revenue increased 0.7% yr/yr but missed analyst expectations

* Adjusted EPS for fiscal Q1 rose to $0.18 from $0.15 a year ago

* Company highlights strategic acquisition of LoveBiome as a pivotal milestone

Outlook

* Company reiterates FY 2026 revenue guidance of $225 mln to $240 mln

* LifeVantage ( LFVN ) expects FY 2026 adjusted EPS of $1.00 to $1.15

* Company anticipates higher H2 revenue due to seasonality and LoveBiome acquisition

Result Drivers

* REGIONAL REVENUE - Revenue in the Americas increased 0.8%, while Asia/Pacific & Europe saw a 0.4% increase, with a decline when excluding currency effects

* EXPENSES IMPACT - Increase in commissions and incentives expenses due to changes in sales mix and promotional programs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 Miss $47.56 $54.75

Revenue mln mln (2

Analysts

)

Q1 Net $2.15

Income mln

Q1 Gross $37.81

Profit mln

Q1 $35.54

Operatin mln

g

Expenses

Q1 $2.26

Operatin mln

g Income

Q1 $2.24

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for LifeVantage Corp ( LFVN ) is $24.00, about 69.4% above its November 3 closing price of $7.34

* The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 12 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)